1 Stibe CMH, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1988;i:403-6. 2 Ray-Chaudhuri K, Critchley P, Abbott RJ, Pye IF, Millac PAH. Subcutaneous apomorphine for on-off oscillations in Parkinson's disease. Lancet 1988;ii:1260. 3 Horowski R. Psychiatric side effects ofhigh dose lisuride therapy in parkinsonism. Lancet 1986;ii:510. 4 Strian F, Micheler E, Beukert 0. Tremor inhibition in parkinson syndrome after apomorphine administration under L-dopa and decarboxylase inhibitor basic therapy. Pharmakopsychiat 1972;5:198-205. 5 Chiara DG, Gessa GL. Pharmacology and neurochemistry of apomorphine. In: Gara Hini S, Goldin A, Hawking F, Kapin IJ, eds. Advances in pharmacology and chemotherapy, Vol 15. London Academic press, 1978, 87-160.
[1]
A. Benabid,et al.
Subcutaneous apomorphine in Parkinson's disease.
,
1989,
Journal of neurology, neurosurgery, and psychiatry.
[2]
W. Poewe,et al.
SUBCUTANEOUS APOMORPHINE IN PARKINSON'S DISEASE
,
1988,
The Lancet.
[3]
A. Lees,et al.
SUBCUTANEOUS APOMORPHINE IN PARKINSONIAN ON-OFF OSCILLATIONS
,
1988,
The Lancet.
[4]
C. Marsden,et al.
L-DOPA esters as potential prodrugs. II: Chemical and enzymatic hydrolysis
,
1985
.
[5]
C. Marsden,et al.
L‐Dopa Methyl Ester—A Candidate for Chronic Systemic Delivery of L‐Dopa in Parkinson's Disease
,
1984,
Clinical neuropharmacology.